公开(公告)号：US12091439B2

公开(公告)日：2024-09-17

申请号：US17589547

申请日：2022-01-31

申请人： Houston Gene Therapeutics LLC

发明人： Paul L. Hermonat

IPC分类号： C12N15/63 ,  A61K9/00 ,  A61K48/00 ,  A61P9/10 ,  C07K14/47 ,  C07K14/54 ,  C12N15/86

CPC分类号： C07K14/5428 ,  A61K9/0019 ,  A61K48/005 ,  A61P9/10 ,  C07K14/47 ,  C07K14/4705 ,  C12N15/86 ,  C07K2319/81 ,  C12N2750/14143

摘要： Provided are various embodiments relating to compositions and methods for treating vascular disease, including core NOX1 promoters and variants thereof for regulating expression of transgenes in response to vascular pathology and allowing for increased transgene loading capacity. Also provided are variant FOXP polypeptides having a zinc finger and leucine zipper region of a different FOXP polypeptide. Further provided are vectors comprising the core NOX1 promoters and/or a coding sequence for variant FOXP polypeptides described herein and optionally coding sequence(s) for one or more additional therapeutic polypeptide(s), such as IL10, for treating inflammation-associated diseases, such as vascular disease. Also provided is a screening model for testing therapeutic agents capable of treating established and ongoing atherosclerotic pathology.

公开(公告)号：US20240301019A1

公开(公告)日：2024-09-12

申请号：US18262648

申请日：2022-02-14

申请人： ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA

发明人： Young-Wook WON ,  Seungmin HAN ,  David A. BULL

IPC分类号： C07K14/47 ,  A61K35/17 ,  A61K38/00 ,  A61P35/00 ,  C12N5/0783

CPC分类号： C07K14/4705 ,  A61K35/17 ,  A61P35/00 ,  C12N5/0646 ,  A61K38/00 ,  C07K2319/09 ,  C07K2319/10 ,  C07K2319/21

摘要： Described herein is a recombinant Eomes protein that restores the cytotoxic activity of exhausted immune cells. This protein comprises, a nuclear localization sequence (NLS), the transcription factor associated domain of Eomesodermin (Eomes), and a protein-transduction domain (PTD). The NLS-Eomes-PTD polypeptide spontaneously internalizes into NK cells and travels to the nucleus to control the transcription of its down-stream signaling pathways. Introduction of the NLS-Eomes-PTD polypeptide into ExNK cells (i) decreases the expression of an inhibitory antigen on ExNK cells; (ii) increases cytolytic activity: (iii) enhances cytokine secretion; (iv) improves proliferation; and (v) inhibits tumor growth.

公开(公告)号：US20240218379A1

公开(公告)日：2024-07-04

申请号：US18339197

申请日：2023-06-21

申请人： Fred Hutchinson Cancer Center

发明人： Shannon K. Oda ,  Philip D. Greenberg ,  Thomas M. Schmitt

IPC分类号： C12N15/62 ,  A61K35/17 ,  C07K14/47 ,  C07K14/705 ,  C07K14/725

CPC分类号： C12N15/62 ,  A61K35/17 ,  C07K14/4705 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/70578 ,  C07K2319/03 ,  C07K2319/33

摘要： The present disclosure relates to immunomodulatory fusion proteins containing an extracellular binding domain and an intracellular signaling domain, wherein binding of a target can generate a modulatory signal in a host cell, such as a T cell. The present disclosure also relates to uses of immune cells expressing such immunomodulatory fusion proteins to treat certain diseases, such as cancer or infectious disease.

公开(公告)号：US20240131193A1

公开(公告)日：2024-04-25

申请号：US18161598

申请日：2023-01-30

申请人： Modema TX, Inc.

发明人： Antonin DE FOUGEROLLES ,  Justin GUILD

IPC分类号： A61K48/00 ,  A61K9/127 ,  A61K9/14 ,  A61K9/51 ,  A61K31/7115 ,  A61K38/17 ,  A61K38/18 ,  A61K38/19 ,  A61K38/21 ,  A61K38/45 ,  A61K38/48 ,  A61K47/54 ,  C07H21/02 ,  C07K14/005 ,  C07K14/435 ,  C07K14/47 ,  C07K14/475 ,  C07K14/485 ,  C07K14/495 ,  C07K14/505 ,  C07K14/515 ,  C07K14/525 ,  C07K14/535 ,  C07K14/54 ,  C07K14/56 ,  C07K14/61 ,  C07K14/62 ,  C07K14/705 ,  C07K14/745 ,  C07K16/00 ,  C07K16/28 ,  C07K16/40 ,  C12N9/00 ,  C12N9/02 ,  C12N9/10 ,  C12N9/12 ,  C12N9/16 ,  C12N9/24 ,  C12N9/42 ,  C12N9/64 ,  C12N9/68 ,  C12N9/88 ,  C12N15/11 ,  C12N15/52 ,  C12N15/85 ,  C12N15/87 ,  C12P13/04 ,  C12P21/00

CPC分类号： A61K48/0066 ,  A61K9/1271 ,  A61K9/145 ,  A61K9/5123 ,  A61K9/5146 ,  A61K9/5153 ,  A61K31/7115 ,  A61K38/17 ,  A61K38/177 ,  A61K38/1816 ,  A61K38/1891 ,  A61K38/191 ,  A61K38/193 ,  A61K38/212 ,  A61K38/45 ,  A61K38/4846 ,  A61K47/543 ,  A61K48/0033 ,  A61K48/005 ,  A61K48/0075 ,  C07H21/02 ,  C07K14/005 ,  C07K14/435 ,  C07K14/43595 ,  C07K14/47 ,  C07K14/4705 ,  C07K14/4713 ,  C07K14/4723 ,  C07K14/4746 ,  C07K14/475 ,  C07K14/485 ,  C07K14/495 ,  C07K14/505 ,  C07K14/515 ,  C07K14/525 ,  C07K14/535 ,  C07K14/5418 ,  C07K14/56 ,  C07K14/61 ,  C07K14/62 ,  C07K14/705 ,  C07K14/745 ,  C07K16/00 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/40 ,  C12N9/0069 ,  C12N9/0091 ,  C12N9/1051 ,  C12N9/1241 ,  C12N9/16 ,  C12N9/2402 ,  C12N9/2445 ,  C12N9/6435 ,  C12N9/6437 ,  C12N9/644 ,  C12N9/6443 ,  C12N9/6451 ,  C12N9/88 ,  C12N9/93 ,  C12N15/11 ,  C12N15/52 ,  C12N15/85 ,  C12N15/87 ,  C12P13/04 ,  C12P21/00 ,  C12P21/005 ,  C12Y603/02019 ,  A61K38/00 ,  Y02A50/30

摘要： The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.

公开(公告)号：US20240124539A1

公开(公告)日：2024-04-18

申请号：US18259637

申请日：2021-12-23

申请人： NEW YORK UNIVERSITY

发明人： Paramjit S. ARORA ,  Seong Ho HONG ,  Daniel YOO

IPC分类号： C07K14/47

CPC分类号： C07K14/4705

摘要： This invention relates to macrostructures (and pharmaceutical formulations containing them) that include an antiparallel coiled-coil. wherein the antiparallel coiled-coil comprises a first coil of Formula I and a second coil of Formula II: T1-g0-a1-b1-c1-d1-e1-f1-g1-a2-b2-c2-d2-e2-f2-g2-a3-b3-c3-d3-e3-f3-T2 (I) T3-f0-g′0-a′1-b′1-c′1-d′1-e′1-f′1-g′1-a′2-b′2-c′2-d′2-e′2-f′2-g′2-a′3-b′3-c′3-d′3-e′3-T4 (II), as described in the present application. Methods of using these macrostructures are also disclosed.

公开(公告)号：US20240092847A1

公开(公告)日：2024-03-21

申请号：US18274306

申请日：2022-01-26

申请人： The University Court of The University of Edinburgh

发明人： Steven Pollard ,  Ute Koeber ,  Mantas Matjusaitis

IPC分类号： C07K14/47 ,  A61K48/00 ,  A61P35/00 ,  C12N9/12 ,  C12N15/86

CPC分类号： C07K14/4705 ,  A61K48/0066 ,  A61P35/00 ,  C12N9/1211 ,  C12N15/86 ,  C12Y207/01021 ,  C07K2319/33 ,  C07K2319/80 ,  C12N2750/14143 ,  C12N2830/008 ,  C12N2830/15

摘要： The disclosure relates to synthetic super-enhancers activated by one or more transcription factors. In particular, the present disclosure describes synthetic super-enhancers that are activated by one or more transcription factors expressed in a target cell and used to express transgenes, such as adverse payloads, upon activation of the synthetic super-enhancer by the transcription factor(s).

公开(公告)号：US20240050592A1

公开(公告)日：2024-02-15

申请号：US18265376

申请日：2021-12-08

申请人： REPAIR BIOTECHNOLOGIES, INC.

发明人： Mourad Topors ,  Reason ,  Guilherme Cherman Perdigao de Oliveira ,  Marc Ridilla ,  David Mackenzie-Liu ,  Garrett Strough

IPC分类号： A61K48/00 ,  C07K14/415 ,  C07K14/705 ,  C07K14/47 ,  A61P3/06 ,  A61K38/17 ,  A61K38/44 ,  C12N15/85 ,  C12N9/02 ,  C12N5/071

CPC分类号： A61K48/0058 ,  C07K14/415 ,  C07K14/705 ,  C07K14/4705 ,  A61P3/06 ,  A61K38/1709 ,  A61K38/443 ,  C12N15/85 ,  C12N9/0081 ,  C12Y114/15006 ,  C12N5/0686 ,  C07K2319/50 ,  C12N2800/107

摘要： Disclosed herein are compositions, methods, and systems for enhancing cholesterol degradation in a cell, tissue, or organism. In many embodiments, the disclosure describes the use of one or more proteins, or sequences coding therefor, to enhance flow of cholesterol into the mitochondrion, where the cholesterol is degraded by one or more proteins comprising bacteria-related sequences. The compositions, methods, and systems disclosed herein are useful in the prevention or treatment of diseases, disorders, and conditions associated with high levels of cholesterol in the blood or cells of a patient.

公开(公告)号：US11891424B2

公开(公告)日：2024-02-06

申请号：US17333406

申请日：2021-05-28

申请人： NELLONE THERAPEUTICS, INC.

发明人： Cymbeline T. Culiat

IPC分类号： A61K38/17 ,  C07K14/47

CPC分类号： C07K14/4705 ,  A61K38/1709 ,  C07K14/47

摘要： Provided are methods for promoting the healing of injuries to tendons and ligaments by administering a NELL1 protein or a nucleic acid encoding a NELL1 protein to a subject in need thereof. Also provided are NELL1 compositions and methods for promoting tissue regeneration, promoting the healing of wounds, and enhancing fibroblast migration, proliferation, or both migration and proliferation.

公开(公告)号：US11851459B2

公开(公告)日：2023-12-26

申请号：US17044602

申请日：2019-04-04

申请人： University of Saskatchewan

发明人： Troy Harkness ,  Terra Gayle Arnason

IPC分类号： C07K14/47 ,  A61P35/00 ,  A61K38/00 ,  A61K45/06

CPC分类号： C07K14/4705 ,  A61P35/00 ,  A61K38/00 ,  A61K45/06

摘要： Methods and uses of activators of the APC complex for treating cancer in a subject, inhibiting the growth of a cancer cell, increasing sensitivity to a cancer treatment in a cancer cell or a subject and/or reducing resistance to a cancer treatment in a cancer cell or a subject.

公开(公告)号：US20230399369A1

公开(公告)日：2023-12-14

申请号：US18304018

申请日：2023-04-20

申请人： UNIVERSITÉ LIBRE DE BRUXELLES

发明人： Benoit VANHOLLEBEKE

IPC分类号： C07K14/47 ,  A61P25/00 ,  G01N33/50

CPC分类号： C07K14/4705 ,  A61P25/00 ,  G01N33/5041 ,  A61K38/00

摘要： Therapeutic agents are capable of activating (GPR)124/RECK/Frizzled/lipoprotein receptor-related protein (LRP)-mediated Wnt signaling. The agents do not activate Frizzled/LRP-mediated Wnt signaling in the absence of RECK and/or GPR124. The agents are particularly useful for the prevention or treatment of neurovascular disorders or central nervous system (CNS) disorders that include neurovascular dysfunction.